{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:16:52Z","timestamp":1790255812950,"version":"4.1.0"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0226552","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T18:27:57Z","timestamp":1577125677000},"page":"e0226552","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-7434","authenticated-orcid":true,"given":"Kibum","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn A.","family":"McMillin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Tantravahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"pone.0226552.ref001","unstructured":"National Cancer Institute. Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL) 2018 [cited 2018 February 1]. https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"issue":"Suppl 2","key":"pone.0226552.ref002","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"M Hoglund","year":"2015","journal-title":"Ann Hematol"},{"key":"pone.0226552.ref003","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary C, et al. SEER Cancer Statistics Review, 1975\u20132014, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2014\/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. Bethesda, MD."},{"key":"pone.0226552.ref004","unstructured":"RED BOOK Online Search- Healthcare Drug Pricing Resource. Micromedex Solutions. Truven Health Analytics Inc. [Internet]. 2017."},{"issue":"4","key":"pone.0226552.ref005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MLR.0000000000000496","article-title":"Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007","volume":"54","author":"PJ Lin","year":"2016","journal-title":"Medical care"},{"issue":"24","key":"pone.0226552.ref006","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"H Kantarjian","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"pone.0226552.ref007","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G Saglio","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"pone.0226552.ref008","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial","volume":"36","author":"JE Cortes","year":"2018","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"19","key":"pone.0226552.ref009","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"JE Cortes","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"7","key":"pone.0226552.ref010","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"WV Padula","year":"2016","journal-title":"Journal of the National Cancer Institute"},{"key":"pone.0226552.ref011","doi-asserted-by":"crossref","first-page":"982395","DOI":"10.1155\/2015\/982395","article-title":"Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis","volume":"2015","author":"U Rochau","year":"2015","journal-title":"Leukemia research and treatment"},{"issue":"Suppl 2","key":"pone.0226552.ref012","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00277-015-2319-x","article-title":"Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU","volume":"94","author":"RM Conti","year":"2015","journal-title":"Annals of hematology"},{"key":"pone.0226552.ref013","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"T O\u2019Hare","year":"2012","journal-title":"Nature Reviews Cancer"},{"issue":"20","key":"pone.0226552.ref014","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"JE Cortes","year":"2016","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"pone.0226552.ref015","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1002\/jcph.937","article-title":"Pharmacokinetic-Guided Dosing of New Oral Cancer Agents","volume":"57","author":"CJ Lucas","year":"2017","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"pone.0226552.ref016","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors","volume":"12","author":"P Herviou","year":"2016","journal-title":"Oncology letters"},{"key":"pone.0226552.ref017","article-title":"Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine","author":"SL Groenland","year":"2019","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6","key":"pone.0226552.ref018","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","article-title":"Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: Results from a randomized controlled trial","volume":"74","author":"V Gotta","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"pone.0226552.ref019","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"},{"key":"pone.0226552.ref020","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1182\/blood.V108.11.4820.4820","article-title":"Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making","volume":"108","author":"C Blasdel","year":"2006","journal-title":"Blood"},{"issue":"3","key":"pone.0226552.ref021","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/leu.2016.246","article-title":"Treatment and outcome of 2904 CML patients from the EUTOS population-based registry","volume":"31","author":"VS Hoffmann","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"pone.0226552.ref022","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","article-title":"Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial","volume":"74","author":"V Gotta","year":"2014","journal-title":"Cancer chemotherapy and pharmacology"},{"issue":"11","key":"pone.0226552.ref023","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.6004\/jnccn.2014.0159","article-title":"Chronic myelogenous leukemia, version 1.2015","volume":"12","author":"S O\u2019Brien","year":"2014","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"issue":"5","key":"pone.0226552.ref024","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12185-011-0838-3","article-title":"Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia","volume":"93","author":"C Yoshida","year":"2011","journal-title":"International journal of hematology"},{"issue":"2","key":"pone.0226552.ref025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"PK Bhamidipati","year":"2013","journal-title":"Therapeutic Advances in Hematology"},{"issue":"8","key":"pone.0226552.ref026","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study","volume":"111","author":"RA Larson","year":"2008","journal-title":"Blood"},{"issue":"6","key":"pone.0226552.ref027","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"M Talpaz","year":"2002","journal-title":"Blood"},{"issue":"3","key":"pone.0226552.ref028","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","article-title":"Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study","volume":"28","author":"JE Cortes","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"10","key":"pone.0226552.ref029","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"E Jabbour","year":"2009","journal-title":"Blood"},{"issue":"10","key":"pone.0226552.ref030","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"F Guilhot","year":"2007","journal-title":"Blood"},{"issue":"10","key":"pone.0226552.ref031","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","article-title":"Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability","volume":"98","author":"N Widmer","year":"2008","journal-title":"British journal of cancer"},{"issue":"5\u20136","key":"pone.0226552.ref032","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000324900","article-title":"Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase","volume":"87","author":"N Takahashi","year":"2011","journal-title":"Pharmacology"},{"issue":"5","key":"pone.0226552.ref033","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"M Miura","year":"2015","journal-title":"Biological & pharmaceutical bulletin"},{"issue":"2","key":"pone.0226552.ref034","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors","volume":"12","author":"P Herviou","year":"2016","journal-title":"Oncology letters"},{"issue":"8","key":"pone.0226552.ref035","doi-asserted-by":"crossref","first-page":"550","DOI":"10.6061\/clinics\/2015(08)04","article-title":"Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors\u2014a single center experience","volume":"70","author":"BF Ribeiro","year":"2015","journal-title":"Clinics (Sao Paulo, Brazil)"},{"issue":"7","key":"pone.0226552.ref036","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up","volume":"89","author":"C Gambacorti-Passerini","year":"2014","journal-title":"American journal of hematology"},{"issue":"7","key":"pone.0226552.ref037","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Y Chen","year":"2013","journal-title":"Leukemia & lymphoma"},{"key":"pone.0226552.ref038","unstructured":"Transplant Outcomes & Data [Internet]. U.S. Department of Health and Human Services. [cited December 21, 2017]. https:\/\/bloodcell.transplant.hrsa.gov\/research\/transplant_data\/index.html."},{"issue":"14","key":"pone.0226552.ref039","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"D Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0226552.ref040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"A Guerin","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"pone.0226552.ref041","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors","volume":"2","author":"K Sasaki","year":"2015","journal-title":"The Lancet Haematology"},{"key":"pone.0226552.ref042","unstructured":"Murphy SL, Xu J, Kochanek KD, Curtin SC, Arias E, Division of Vital Statistics. Deaths: Final Data for 2015. Hyattsville, MD: U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, Centers for Disease Control and Prevention"},{"issue":"3","key":"pone.0226552.ref043","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/leu.2015.281","article-title":"Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment","volume":"30","author":"A Gratwohl","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"pone.0226552.ref044","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5639\/gabij.2017.0602.016","article-title":"Overview of the patent expiry of (non-) tyrosine kinase inhibitors approved for clinical use in the EU and the US","volume":"6","author":"S Venkatesan","year":"2017","journal-title":"Generics and Biosimilars Initiative Journal"},{"key":"pone.0226552.ref045","unstructured":"Physician Fee Schedule [Internet]. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/PhysicianFeeSched\/."},{"key":"pone.0226552.ref046","unstructured":"National and regional estimates on hospital use for all patients from the HCUP National (Nationwide) Inpatient Sample (NIS) [Internet]. U.S. Department of Health & Human Resources,. [cited August 20, 2017]. https:\/\/hcupnet-archive.ahrq.gov\/HCUPnet.jsp?Id=2015F1A3BA540EB5&Form=MAINSEL&JS=Y&Action=%3E%3ENext%3E%3E&_MAINSEL=National%20Statistics."},{"issue":"5","key":"pone.0226552.ref047","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00019053-200826050-00007","article-title":"Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia","volume":"26","author":"SD Reed","year":"2008","journal-title":"PharmacoEconomics"},{"issue":"2","key":"pone.0226552.ref048","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","article-title":"Costs of allogeneic hematopoietic cell transplantation with high-dose regimens","volume":"14","author":"AM Saito","year":"2008","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"key":"pone.0226552.ref049","unstructured":"Medical care commodities in U.S. city average, all urban consumers, not seasonally adjusted [Internet]. [cited September 15, 2017]. https:\/\/beta.bls.gov\/dataQuery\/find?fq=survey:[cu]&s=popularity:D."},{"issue":"11","key":"pone.0226552.ref050","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.20694","article-title":"Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"SD Reed","year":"2004","journal-title":"Cancer"},{"issue":"5","key":"pone.0226552.ref051","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00019053-200523050-00010","article-title":"Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia","volume":"23","author":"K Dalziel","year":"2005","journal-title":"PharmacoEconomics"},{"issue":"2","key":"pone.0226552.ref052","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0272989X9301300202","article-title":"The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors","volume":"13","author":"DG Fryback","year":"1993","journal-title":"Medical decision making: an international journal of the Society for Medical Decision Making"},{"issue":"12","key":"pone.0226552.ref053","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.7326\/0003-4819-127-12-199712150-00005","article-title":"Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis","volume":"127","author":"SJ Lee","year":"1997","journal-title":"Annals of internal medicine"},{"key":"pone.0226552.ref054","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-2-35","article-title":"Acute graft versus host disease","volume":"2","author":"DA Jacobsohn","year":"2007","journal-title":"Orphanet journal of rare diseases"},{"issue":"12","key":"pone.0226552.ref055","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"R Hehlmann","year":"2011","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"3","key":"pone.0226552.ref056","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"J Cortes","year":"2019","journal-title":"American journal of hematology"},{"key":"pone.0226552.ref057","first-page":"1621","article-title":"Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience","volume":"130","author":"N Shanmuganathan","year":"2017","journal-title":"Blood"},{"issue":"1","key":"pone.0226552.ref058","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"TP Hughes","year":"2016","journal-title":"Blood"},{"issue":"4","key":"pone.0226552.ref059","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"DM Ross","year":"2013","journal-title":"Blood"},{"issue":"1","key":"pone.0226552.ref060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"F-X Mahon","year":"2017","journal-title":"Hematology American Society of Hematology Education Program"},{"issue":"10","key":"pone.0226552.ref061","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"A Hochhaus","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"11","key":"pone.0226552.ref062","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"SG O\u2019Brien","year":"2003","journal-title":"The New England journal of medicine"},{"issue":"24","key":"pone.0226552.ref063","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"G Saglio","year":"2010","journal-title":"The New England journal of medicine"},{"issue":"23","key":"pone.0226552.ref064","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","volume":"23","author":"JY Kwak","year":"2017","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"23","key":"pone.0226552.ref065","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"BJ Druker","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"10","key":"pone.0226552.ref066","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clml.2015.06.006","article-title":"The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients with Chronic Myeloid Leukemia in the Community Setting","volume":"15","author":"NJ Di Bella","year":"2015","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"5","key":"pone.0226552.ref067","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1200\/JOP.2012.000822","article-title":"Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia","volume":"9","author":"N Vander Velde","year":"2013","journal-title":"Journal of oncology practice"},{"issue":"7","key":"pone.0226552.ref068","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"A Gu\u00e9rin","year":"2014","journal-title":"Current Medical Research and Opinion"},{"issue":"9","key":"pone.0226552.ref069","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/jch.12570","article-title":"Cost Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients with Resistant Hypertension","volume":"17","author":"A Velasco","year":"2015","journal-title":"Journal of clinical hypertension (Greenwich, Conn)"},{"issue":"12","key":"pone.0226552.ref070","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1097\/HJH.0000000000000346","article-title":"Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension","volume":"32","author":"O Chung","year":"2014","journal-title":"Journal of hypertension"},{"issue":"2","key":"pone.0226552.ref071","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3111\/13696998.2013.862251","article-title":"Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia","volume":"17","author":"A Guerin","year":"2014","journal-title":"J Med Econ"},{"key":"pone.0226552.ref072","unstructured":"U.S. Transplant Data by Center Report [Internet]. [cited November 22, 2017]. https:\/\/bloodcell.transplant.hrsa.gov\/research\/transplant_data\/us_tx_data\/data_by_center\/center.aspx."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T09:46:13Z","timestamp":1695548773000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0226552"}},"subtitle":[],"editor":[{"given":"Chung Hoow","family":"Kok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":72,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0226552","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]}}}